WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Company management will present at two investor conferences in the coming weeks. The live webcast of each presentation can be accessed through the “Investor Information” section of the Company’s website, www.immunogen.com; a replay of each presentation will be available at the same location for one week.
